Background & Aims: Immune checkpoint inhibitors (ICIs) show heterogeneous efficacy in advanced hepatocellular carcinoma (HCC), but existing biomarkers are invasive and costly. We aimed to develop a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback